Related Experiment Videos
Chronic myeloid leukemia in the imatinib era
1Howard Hughes Medical Institute and the School of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA.
Seminars in Hematology
|June 5, 2003
Abstract:
The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.